QL1706 (Iparomlimab/Tuvonralimab)
QILIN-01
Phase 2 small_molecule active
Quick answer
QL1706 (Iparomlimab/Tuvonralimab) for Gastric Cancer Stage III is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Gastric Cancer Stage III
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active